Medical Devices - Orthobiologics and Spinal Implants
Strategic Profile
Xtant Medical is executing a strategic transformation to concentrate on its core orthobiologics business and develops a comprehensive portfolio of regenerative products designed to promote bone and tissue healing in spinal and orthopedic procedures. The company has established exceptional market access through 450 integrated delivery network contracts and a network of more than 670 independent distributors.
Cyborg Score Rationale
The company's Altman Z-Score of -0.56 places Xtant in the distress zone, implying a potential risk of financial instability. However, Q1 2025 showed revenue increases of 18% year-over-year with positive net income and $1.3 million in operating cash flow. Strategic divestitures are providing liquidity but execution risk remains.
Top Insights
Xtant's vertically integrated platform includes all five major orthobiologic categories with a comprehensive portfolio covering demineralized bone graft, cellular allograft, allograft, synthetic bone graft, and marrow-derived growth factor products.
Recent divestitures of Coflex assets and Paradigm OUS operations with total proceeds of $21.4 million are part of strategic realignment to improve liquidity and reduce debt.
The company achieved three straight quarters of positive adjusted EBITDA with annual gross margin improvements of 540 basis points in 2023.
Named Competitors
Orthobiologic and Spinal Implant Solutions — Orthobiologic and bone healing solutions
Regenerative Medicine Products — Cardiovascular and orthopedic tissue solutions
Spinal Fusion Systems — Sacroiliac joint fusion devices
Recent Developments
(March 2026) Completed asset sale to Companion Spine with final $10.7M payment, bringing total divestitures to $21.4M for debt reduction and liquidity enhancement
(November 2025) Q3 2025 revenue of $33.3M increased 19% YoY with positive net income and adjusted EBITDA; maintained FY25 guidance of $131-$135M
(May 2025) Q1 2025 revenue increased 18% YoY with positive net income; raised 2025 revenue guidance to $127-$131M
(August 2025) Announced strategic asset sale of Coflex and Paradigm OUS operations to Companion Spine for approximately $19.2M to reduce debt and improve liquidity
Open the full interactive Xtant Medical Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.